Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis

Inclusion Criteria: * written informed consent * aged 18-70 years * clinical diagnosis of compensated liver cirrhosis 1. liver biopsy showing cirrhosis 2. endoscopy: esophageal varices , exclusion of noncirrhotic portal hypertension 3. if no biopsy or endoscopy ，should meet two of the four: * Imaging(US, CT or MRI, et al) showing Surface nodularity： Echogenecity （spleen pachydiameter \> 4.0cm or\> 5 costal region） * PLT \< 100×10 \< 9 \>/L，no other interpretation * ALB \< 35.0 g/L, or INR \> 1.3, or CHE \< 5.0KU/L * Liver stiffness measurement value \> 12.4 kpa * HBeAg(+)with HBVDNA \> 10 \< 3 \> IU/mL or HBeAg(-) wtih HBVDNA \> 102 IU/mL Exclusion Criteria: * patient with decompensated liver cirrhosis:presence of ascites, variceal hemorrhage,hepatic encephalopathy * allergic to any ingredients of the drugs * patient complicated with alcoholic liver disease, autoimmune liver disease, heretic liver disease, drug induced liver disease,nonalcoholic liver disease or other chronic liver disease. * AFP \> 100ng/ml or Cr \> 1.5×ULN * pregnant woman * patient with severe disease or other organ failure * patient with any tumors * patient with sever mental disease. * patients with any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject